Industry welcomes Energy and Commerce paper to help expedite clinical trials

By Dan Stanton

- Last updated on GMT

United States House Committee on Energy and Commerce
United States House Committee on Energy and Commerce

Related tags Clinical trial

Guidance to remove red tape in the clinical trial process has been commended by the industry body ACRO.

A discussion document forming part of the 21st Century Cures initiative has been released compiling discussions and ideas from both Democrats and Republicans as to how to approach the future of the drug development process.

The paper produced by the House Energy and Commerce Committee is embedded below, and includes a proposal to reduce administrative delays in the clinical trial process by removing the “antiquated framework”​ set up before trials involved multiple investigators across a number of different trial sites, including the need for each proposed trial to have an institutional review board (IRB) approval before patient recruitment even begins.

Furthermore, the proposed Clinical Research Modernization Act discussed in the guidance would “stipulate that clinical trials subject to FDA regulations should not also be subject to the duplicative—and sometimes conflicting—provisions known as the Common Rule under the Public Health Service Act.”

The paper, unveiled by Committee Chairman and US Representative Fred Upton, was applauded by Doug Peddicord, Executive Director of the Association of Clinical Research Organizations (ACRO) who said the document “provides the outline for a solid framework”​  to improve the clinical trial process for the benefit of patients.

“We are particularly encouraged by draft proposals to enhance data sharing and make greater use of real world evidence, streamline the review process for clinical trials, and make a more useable tool for patients, physicians and researchers.”

The guidance also includes draft provisions to incorporate patient perspectives into the regulatory process, modernize medical product regulation, build on the 21st​ Century Medicine foundation, and support continued innovation in R&D.

It was also commended by industry group the Biotechnology Industry Organization (BIO) which contributed to the discussions which formed the document.

“Working with member companies, patient advocacy groups, and other stakeholders, we developed numerous proposals to create a public policy environment that encourages the use of 21st century scientific tools, advancements in molecular biology, and novel bioinformatics to continuously develop and improve upon therapies that can prevent, diagnose and treat all stages of disease,”​ said CEO Jim Greenwood.

“We are pleased to see several of our priority suggestions in the discussion draft, including the need for a large-scale national research commitment to study precursors and signs of disease and disease risk factors for chronic conditions.”

Related news

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us


View more